Franklin Street Advisors’s ProQR Therapeutics PRQR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $279K | Hold |
150,000
| – | – | 0.02% | 155 |
|
|
2026
Q1 | $243K | Hold |
150,000
| – | – | 0.01% | 151 |
|
|
2025
Q4 | $303K | Hold |
150,000
| – | – | 0.02% | 141 |
|
|
2025
Q3 | $320K | Hold |
150,000
| – | – | 0.02% | 135 |
|
|
2025
Q2 | $306K | Hold |
150,000
| – | – | 0.02% | 139 |
|
|
2025
Q1 | $200K | Hold |
150,000
| – | – | 0.01% | 157 |
|
|
2024
Q4 | $398K | Hold |
150,000
| – | – | 0.03% | 123 |
|
|
2024
Q3 | $273K | Hold |
150,000
| – | – | 0.02% | 148 |
|
|
2024
Q2 | $249K | Hold |
150,000
| – | – | 0.02% | 148 |
|
|
2024
Q1 | $343K | Hold |
150,000
| – | – | 0.03% | 124 |
|
|
2023
Q4 | $297K | Hold |
150,000
| – | – | 0.02% | 126 |
|
|
2023
Q3 | $195K | Hold |
150,000
| – | – | 0.02% | 143 |
|
|
2023
Q2 | $243K | Hold |
150,000
| – | – | 0.02% | 130 |
|
|
2023
Q1 | $320K | Hold |
150,000
| – | – | 0.03% | 109 |
|
|
2022
Q4 | $555K | Hold |
150,000
| – | – | 0.05% | 94 |
|
|
2022
Q3 | $112K | Hold |
150,000
| – | – | 0.01% | 136 |
|
|
2022
Q2 | $117K | Buy |
150,000
+50,000
| +50% | +$37.3K | 0.01% | 143 |
|
|
2022
Q1 | $91K | Sell |
100,000
-10,000
| -9% | -$33.5K | 0.01% | 154 |
|
|
2021
Q4 | $881K | Buy |
110,000
+10,000
| +10% | +$76.1K | 0.07% | 89 |
|
|
2021
Q3 | $837K | Hold |
100,000
| – | – | 0.07% | 88 |
|
|
2021
Q2 | $674K | Hold |
100,000
| – | – | 0.06% | 95 |
|
|
2021
Q1 | $661K | Buy |
100,000
+40,000
| +67% | +$204K | 0.06% | 97 |
|
|
2020
Q4 | $252K | Hold |
60,000
| – | – | 0.02% | 129 |
|
|
2020
Q3 | $287K | Hold |
60,000
| – | – | 0.03% | 117 |
|
|
2020
Q2 | $365K | Hold |
60,000
| – | – | 0.04% | 108 |
|
|
2020
Q1 | $329K | Hold |
60,000
| – | – | 0.05% | 102 |
|
|
2019
Q4 | $595K | Hold |
60,000
| – | – | 0.07% | 97 |
|
|
2019
Q3 | $346K | Hold |
60,000
| – | – | 0.04% | 117 |
|
|
2019
Q2 | $546K | Hold |
60,000
| – | – | 0.07% | 101 |
|
|
2019
Q1 | $832K | Hold |
60,000
| – | – | 0.12% | 83 |
|
|
2018
Q4 | $947K | Hold |
60,000
| – | – | 0.15% | 81 |
|
|
2018
Q3 | $1.16M | Sell |
60,000
-30,000
| -33% | -$319K | 0.16% | 80 |
|
|
2018
Q2 | $657K | Buy |
90,000
+30,000
| +50% | +$151K | 0.1% | 87 |
|
|
2018
Q1 | $185K | Buy |
+60,000
| New | +$193K | 0.03% | 153 |
|
Other funds holding PRQR
Franklin Street Advisors's PRQR Position: Q2 2026 in Review
Franklin Street Advisors held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 150,000 shares worth $279K. The position accounts for 0.02% of the portfolio, ranked #155.
Franklin Street Advisors first reported a position in PRQR in Q1 2018 and has held it in 34 quarters since. The position peaked at $1.16M in Q3 2018. 3 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.
- Franklin Street Advisors held 150,000 shares of ProQR Therapeutics worth $279K as of Q2 2026.
- Franklin Street Advisors left its ProQR Therapeutics share count unchanged in Q2 2026.
- ProQR Therapeutics made up 0.02% of Franklin Street Advisors's portfolio in Q2 2026, its #155 holding.
- Franklin Street Advisors first reported a position in ProQR Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Franklin Street Advisors's ProQR Therapeutics position peaked at $1.16M in Q3 2018.
- 3 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.
Based on Franklin Street Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.